Comparison
CagriSema vs. Survodutide
Two peptides side-by-side — identity, evidence base, legal status and known adverse events.
Identity
Category
Metabolic
Metabolic
CAS no.
no data
2179963-22-7
Molecular weight
no data
4727 g/mol
Half-life
no data
168 h
Sequence
no data
modifiziertes 29-Aminosäuren-Peptid mit FettsäureseitenketteMechanism of action
CagriSema
CagriSema combines two satiety pathways in one weekly injection: the amylin analogue cagrilintide and the GLP-1 agonist semaglutide. Both suppress appetite and food intake — together more than either component alone.
Survodutide
Survodutide is a dual agonist at the GLP-1 and glucagon receptors. The GLP-1 component mediates glucose-dependent insulin secretion, inhibition of glucagon secretion at high blood glucose and modulation of satiety. The glucagon component raises basal energy expenditure via hepatic and brown adipocyte effects. A fatty-acid side chain enables albumin binding and weekly dosing.
Evidence base
Highest evidence
Human RCT
Human RCT
Studies
1
4
of which in humans
1
4
Effects recorded
2
3
Open conflicts
0
1
Documented adverse events
1
2
Legal status
Full entries
Frequently asked questions
- What is the difference between CagriSema and Survodutide?
- CagriSema is classified as "Metabolic", while Survodutide is classified as "Metabolic". CagriSema: CagriSema is a fixed-dose combination of the amylin analogue cagrilintide and the GLP-1 agonist semaglutide (Novo Nordisk), in late-stage development for obesity and type 2 diabetes. Survodutide: Synthetic peptide that simultaneously activates the GLP-1 and glucagon receptors. Developed by Boehringer Ingelheim and Zealand Pharma; in phase-3 trials for obesity (SYNCHRONIZE) and MASH. No marketing approval yet. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
- Which peptide is better supported by science, CagriSema or Survodutide?
- The highest available evidence level is "Human RCT" for CagriSema and "Human RCT" for Survodutide. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
- What is the legal status of CagriSema and Survodutide in Germany and the United States?
- Germany: CagriSema — Unapproved, Survodutide — Unapproved. United States: CagriSema — Unapproved, Survodutide — Unapproved. These are factual summaries with source and review date on the individual pages.